Oseltamivir plus usual care vs usual care for influenza-like illness in primary care: An open-label, pragmatic, randomized controlled trial

The Lancet Dec 18, 2019

Butler CC, van der Velden AW, Bongard E, et al. - In this open-label, pragmatic, adaptive, randomized controlled trial of adding oseltamivir to usual care in patients aged 1 year and older presenting with influenza-like illness in primary care, experts ascertained whether adding antiviral treatment to usual primary care for individuals with influenza-like illness decreased time to recovery overall and in chief subgroups. Between Jan 15, 2016, and April 12, 2018, 3,266 people in 15 European countries during three seasonal influenza seasons were enrolled, allocated to usual care plus oseltamivir (n = 1,629) and to usual care (n = 1,637). Compared with those managed by usual care alone, primary care individuals with influenza-like illness treated with oseltamivir recovered one day sooner on average. Moreover, elderly, sicker people with comorbidities and longer former symptom duration recovered 2–3 days sooner.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen